Cbio A/S
Cleanroom operator cutting tumor tissue
Picture of Cbio cleanroom operator cutting tumor tissue for T-cell therapy production
SØBORG, Denmark, April 12, 2024 (GLOBE NEWSWIRE) — Cbio A/S – Pioneering Next-Gen T-Cell Therapies for Solid Tumors, Unveils 2023 Financial Results and Company Updates.
Ulrik Cordes, Founder & CEO of Cbio, stated: “2023 was another great year for Cbio. We finalized the preclinical development of our lead T-cell therapy asset, novoleucel and made considerable progress in preparing for our upcoming phase I/II clinical trial at Karolinska, where we will treat 20 patients with late-stage cervical cancer.
Ulrik Cordes continues: “Our top priority for 2024 is to start our first clinical trial, thereby reaching a major value inflection point. Within the T-cell therapy space, Cbio holds a strong position, and we are dedicated to driving the industry…
